{"entity":{"id":"burjeel-medical-city","kind":"institution","name":"Burjeel Medical City and Burjeel Cancer Institute, Abu Dhabi","aka":["Burjeel Cancer Institute","Burjeel Medical City","VPS Healthcare"],"tldr":"A private hospital in Abu Dhabi whose cancer institute gives chemotherapy, radiotherapy and, since 2026, radiopharmaceutical treatment for some cancers that have spread. It is a site for international breast and lung cancer trials.","summary":"In its UICC directory entry (updated May 2026) Burjeel Medical City describes diagnosis, staging and treatment of solid tumours and blood cancers, a weekly multidisciplinary meeting with radiology, pathology, radiation and PET services, neoadjuvant, adjuvant and palliative chemotherapy, a tumour registry that reports to the Department of Health, and free screening and awareness days. IAEA DIRAC, read on 11 November 2026 with the entry updated in 2025, lists the Burjeel Cancer Institute with two linear accelerators and a CT scanner. In October 2026 the Abu Dhabi Media Office reported that the institute had introduced therapeutic radiopharmaceuticals, delivered in Burjeel Medical City's nuclear medicine department, for patients with tumours that express the target receptors. ClinicalTrials.gov lists it as a site of the heredERA trial of giredestrant in HER2-positive breast cancer (NCT05296798) and of the trial of sacituzumab tirumotecan with pembrolizumab in squamous lung cancer (NCT06422143).","asOf":"2026-11-11","links":[{"label":"UICC member directory: Burjeel Medical City, VPS Healthcare","url":"https://www.uicc.org/membership/burjeel-medical-city-vps-healthcare-llc"},{"label":"IAEA DIRAC: radiotherapy centres and equipment (read 11 November 2026)","url":"https://dirac.iaea.org/Data/CountriesLight"},{"label":"Abu Dhabi Media Office: Burjeel Cancer Institute introduces radiopharmaceutical therapy (16 October 2026)","url":"https://www.mediaoffice.abudhabi/en/health/burjeel-cancer-institute-in-abu-dhabi-introduces-targeted-radiopharmaceutical-therapy-for-certain-metastatic-tumours/"},{"label":"ClinicalTrials.gov NCT05296798: site list","url":"https://clinicaltrials.gov/study/NCT05296798"},{"label":"ClinicalTrials.gov NCT06422143: site list","url":"https://clinicaltrials.gov/study/NCT06422143"}],"tags":[],"related":[],"cancers":["breast-cancer","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tawam-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Abu Dhabi","country":"AE","lat":24.354,"lng":54.539,"institutionType":"hospital","website":"https://burjeel.com","programs":["Medical oncology and haematology","Radiotherapy (two linear accelerators in IAEA DIRAC)","Radiopharmaceutical therapy (from 2026)"]},"route":"/institutions/burjeel-medical-city/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"institution":[{"id":"emirates-drug-establishment","kind":"institution","name":"Emirates Drug Establishment (EDE)","route":"/institutions/emirates-drug-establishment/"},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/"}],"trial":[{"id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/"},{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/"}]}}